Browse the evidence

Transoral outlet reduction (TORe) using argon plasma coagulation (APC) induces a significant increase in postprandial peptide YY (PYY) levels, particularly in patients who have undergone cholecystectomy, whereas APC combined with suturing does not produce this effect.

If you have regained weight after gastric bypass due to a stretched connection (anastomosis), endoscopic tightening with argon plasma coagulation (APC) may help restore your body's natural satiety signals, specifically Peptide YY (PYY). This effect is particularly strong if you have had your gallbladder removed. This suggests that choosing the right endoscopic technique (APC vs. suturing) matters for hormonal health and potentially long-term weight management.

Transoral outlet reduction (TORe) delays the postprandial decrease in ghrelin levels by approximately 30 minutes, shifting the nadir from 30 minutes to 60-90 minutes, without significantly altering the total ghrelin exposure (AUC) or correlating with clinical success.

TORe changes *when* you feel hungry after eating, not necessarily *how much* hunger hormone is produced overall. Specifically, it delays the drop in hunger hormones (ghrelin) by about 30 minutes. This might help you feel full a bit longer after a meal, but this specific hormonal change does not predict whether you will successfully lose weight.

One year after TORe, patients experience a significant overall decrease in postprandial Glucagon-like peptide-1 (GLP-1) levels, regardless of the specific technique used (APC vs. suture) or clinical success status.

After TORe, your levels of GLP-1 (a hormone that helps regulate blood sugar and satiety) tend to drop significantly one year later. Despite this drop, patients often still see improvements in blood sugar and lipids. This suggests that weight loss and other factors are more important for metabolic health than GLP-1 levels alone.

Gastric greater curvature plication combined with Nissen fundoplication (GGCP + Nissen) produces significantly less long-term weight loss and inferior glucose homeostasis compared to sleeve gastrectomy (SG) in patients with obesity and type 2 diabetes models, despite being effective for GERD resolution.

If you have obesity and significant acid reflux, standard sleeve gastrectomy might worsen your reflux. A combined procedure (plication + Nissen) can fix your reflux and provide moderate weight loss, but it is less effective for weight loss and blood sugar control than standard sleeve gastrectomy. Choose based on whether reflux control or maximum weight loss is your primary goal.

Self-managed lifestyle interventions (diet and exercise) are the primary initial weight loss strategy in China, but they result in low compliance and modest efficacy, leading to a high unmet need for anti-obesity medications (AOMs).

If you are in China and trying to lose weight, know that self-managed diet and exercise are the standard first steps, but they often fail due to low compliance. If lifestyle changes aren't working, it is not your fault; the current options have limitations. Discuss anti-obesity medications (AOMs) with your doctor, as new options are becoming available and are desired by both patients and physicians for better efficacy and safety.

Anti-obesity medications (AOMs) are underutilized in China due to limited approved options and physician preference for lifestyle interventions, despite high patient willingness to try new AOMs.

If you are a physician in China, be aware that AOMs are underutilized due to limited options and safety concerns. However, patients are willing to try new AOMs. As new AOMs become available, consider prescribing them for patients who fail lifestyle interventions.

GLP-1 receptor agonists (specifically liraglutide) exert direct anti-inflammatory and chondroprotective effects in osteoarthritis by suppressing NF-κB activation, reducing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), and downregulating cartilage-degrading enzymes (MMPs, ADAMTS), while promoting type II collagen synthesis.

Research shows that GLP-1 drugs may protect knee cartilage directly by reducing inflammation and stopping enzymes that break down joint tissue, in addition to helping you lose weight. This suggests these drugs might slow the progression of osteoarthritis, not just mask the pain.

GLP-1 receptor agonists reduce the incidence of knee surgeries and slow cartilage loss in patients with knee osteoarthritis and type 2 diabetes, as demonstrated in real-world observational cohorts.

For patients with knee OA and diabetes, using GLP-1 drugs like liraglutide or semaglutide is associated with a lower risk of needing knee surgery and slower loss of knee cartilage compared to not using these drugs. This suggests they may help preserve joint structure over time.

The gut microbiota causally influences obesity and metabolic disorders by modulating the secretion of gut hormones (GLP-1, ghrelin, PYY) and influencing hypothalamic neuroendocrine pathways, suggesting microbiota-based therapies as a potential treatment.

While microbiota-based therapies are still being researched, the gut microbiome plays a role in regulating appetite hormones like GLP-1 and ghrelin. Dietary patterns that support a healthy microbiome may contribute to better metabolic health and weight management.

GLP-1 receptor agonists (specifically Exendin-4, Liraglutide, and native GLP-1) modulate human mesenchymal stem cell (hMSC) function by promoting osteogenesis and inhibiting adipogenesis through context-, dose-, and timing-dependent mechanisms.

GLP-1 medications (like Ozempic or Trulicity) are primarily used for diabetes and weight loss, but research suggests they also interact with your body's stem cells. Specifically, they appear to encourage bone-forming cells to work better while discouraging fat-storing cells from differentiating. This effect depends heavily on the specific drug, the dose, and the timing of exposure. While this is promising for regenerative medicine, it is currently based on lab studies, not human clinical trials for tissue repair.

Ghrelin, the only gastrointestinal hormone that increases appetite, stimulates dopamine release in the VTA to increase food motivation and sex motivation in males, but reduces sex motivation in females during lactation.

Ghrelin increases hunger and food motivation by stimulating dopamine release in the brain. In males, it may also increase sex motivation, while in lactating females, it may reduce sex motivation to prioritize maternal care. Understanding these hormonal signals can help manage hunger and motivated behaviors.

During the stable weight maintenance phase, the appetite-suppressing effects of GLP-1 medications may diminish for some patients, leading to a gradual return of hunger, cravings, and food noise, though often less intense than pre-treatment levels.

If you are on long-term GLP-1 medication and notice your hunger or cravings returning slightly, this is a known phenomenon called the 'stable phase' transition. It does not necessarily mean the drug has failed. You may need to adjust your eating habits or discuss dose adjustments with your doctor. The return of hunger is often less severe than before treatment.

Combination therapy using atomoxetine and oxybutynin reduces OSA severity by approximately 60% by activating pharyngeal dilator muscles.

This combination drug is currently in clinical trials (Phase III) and not yet widely available. It targets the muscle function aspect of sleep apnea. If you are not a candidate for CPAP or weight loss drugs, you may want to ask your doctor about upcoming clinical trials for this specific combination.

Carbonic anhydrase inhibitors such as acetazolamide reduce OSA severity by 40-50% in patients with high loop gain.

If you have high loop gain OSA, ask your doctor about carbonic anhydrase inhibitors like acetazolamide. These can reduce your apnea severity by 40-50% by stabilizing your breathing control. Be aware of potential side effects like tingling or stomach upset.

Brown adipose tissue (BAT) activation and white-to-brown adipose tissue transformation reduce obesity risk by increasing energy expenditure and improving glucose homeostasis.

Focus on strategies that may support metabolic health and energy expenditure, such as exposure to cold or specific dietary patterns, as these may influence brown fat activity. However, consult a healthcare provider for personalized advice, as this is a complex physiological area.

Leptin resistance, caused by impaired blood-brain barrier transport or receptor signaling defects, prevents the hormone from suppressing appetite and regulating body weight in obese individuals.

Understanding leptin resistance highlights why simple calorie counting might fail. It suggests that metabolic health, including blood-brain barrier integrity and receptor sensitivity, is crucial. Work with a healthcare provider to address underlying metabolic health.

GLP-1 receptor agonists (semaglutide and liraglutide) are primarily requested by the public for off-label cosmetic weight loss, often without prescriptions or medical advice, creating a high risk of misuse and safety concerns.

GLP-1 medications like semaglutide and liraglutide are powerful tools for weight management and diabetes, but they are not cosmetic shortcuts. Most requests for these drugs are for weight loss without a prescription, which poses safety risks. If you are considering these medications, consult a healthcare provider to ensure they are appropriate for your health needs and to receive proper guidance on usage and side effects.

GLP-1 receptor agonists and dual incretin therapies (semaglutide, liraglutide, tirzepatide) do not show a disproportional reporting signal for suicidal ideation or suicide attempt compared to non-GLP-1 anti-obesity drugs.

Current pharmacovigilance data does not support a causal link between GLP-1 or dual incretin weight-loss drugs and suicidal ideation or attempts. While patients should be monitored as standard practice, the absolute risk appears neutral compared to other anti-obesity medications.

Non-GLP-1 anti-obesity drugs, specifically naltrexone/bupropion, show elevated disproportional reporting signals for suicidal ideation and suicide attempt compared to GLP-1/dual incretin therapies.

Naltrexone/bupropion shows a higher reporting signal for suicidality compared to GLP-1 drugs, which is consistent with its known pharmacology. Patients using this medication should be monitored for mood changes.

Modifying structural and social determinants of health (SDOH), such as housing and economic stability, is a necessary lever for achieving health equity in obesity treatment, as individual-level interventions alone fail to address root causes of disparities.

To improve obesity outcomes for marginalized groups, interventions must go beyond diet and exercise advice. They need to address structural barriers like housing stability and income. Policy changes and community-level investments are essential to create equitable opportunities for health.

Semaglutide and liraglutide have similar anti-hyperglycemic efficacy, with no consistent significant difference in HbA1c reduction between the two drugs.

For patients with type 2 diabetes, choosing between semaglutide and liraglutide should likely be based on weight loss goals and injection frequency preference, as both drugs lower blood sugar similarly.

Long-term maintenance of significant weight loss (>10%) following a Very Low Calorie Diet (VLCD) is rare, with only 5.9% of healthy participants sustaining loss after 15 years.

VLCD can help you lose weight quickly, but it is not a permanent fix. Without ongoing lifestyle changes, most people regain the weight within 15 years. Use it as a starting point, not a solution.

Greater weight loss achieved during VLCD is associated with a higher incidence of cardiovascular events in the 15 years following the intervention.

Losing a lot of weight quickly might not protect your heart in the long run if you regain it. Focus on steady, sustainable habits rather than extreme loss.

VLCD does not prevent the development of type 2 diabetes or impaired fasting glucose in the long term (15 years) for the majority of participants.

VLCD might put diabetes into remission for a short time, but it rarely prevents it long-term. You must maintain a healthy weight to keep blood sugar stable.